Home > Press Releases > Personalized Oncology Market

Personalized Oncology Market Likely to Surpass USD 18.4 Billion by 2035

Report Code: HC-73035  |  Published in: Jul 2026, By MarketGenics  |  Number of pages: 367
Get PDF
Buy

Global Personalized Oncology Market Forecast 2035:

According to the report, the global personalized oncology market is projected to expand from USD 7.7 billion in 2025 to USD 18.4 billion by 2035, registering a CAGR of 9.1%, the highest during the forecast period. The personalized oncology market is growing as comprehensive genomic profiling is gaining traction to better characterize tumors and select personalized treatments.  

The growing adoption of companion diagnostics and AI is enhancing biomarker identification, clinical decision-making, and targeted cancer therapy development. For instance, in January 2026, Natera, Inc. announced new clinical data to support expanded use of its Signatera MRD assay for multiple solid tumors.  

Furthermore, the American Society of Clinical Oncology is working to advance biomarker-driven treatment guidelines and the implementation of precision medicine, to encourage greater adoption of genomic testing for all patients with cancer in routine clinical care, and to support the development of targeted therapy across a range of cancer types. The continued advancement of genomic technologies and growing use of biomarkers in healthcare are driving the adoption and commercialization of personalized oncology globally.                   

Key Driver, Restraint, and Growth Opportunity Shaping the Global Personalized Oncology Market

The increasing use of liquid biopsy technologies for non-invasive cancer detection and treatment monitoring is driving the personalized oncology market. By allowing for real-time monitoring of tumor evolution, early detection of resistance mutations and ongoing assessment of therapeutic response, liquid biopsy can also help to minimize the need for invasive tissue biopsies while providing the ability to deliver more precise, adaptive treatment strategies.                                   

The availability of high-quality, clinically annotated genomic datasets continues to be a significant restrain on the personalized oncology market. Clinical adoption and research are hindered by fragmented or incomplete molecular and clinical data, which hinders biomarker discovery, AI model building and precision treatment recommendations.                     

The rise of spatial biology and spatial transcriptomics opens up great potential for the personalized oncology market. The technologies offer exclusive insights into the tumor microenvironment and cellular communications, as well as the identification of novel biomarkers, patient stratification, and the development of new generation targeted therapies and precision immuno-oncology strategies.                                   

Expansion of the Global Personalized Oncology Market

Expansion of Liquid Biopsy for Early Cancer Detection and Disease Monitoring

  • The personalized oncology market is being propelled by the growing popularity of liquid biopsies for early cancer diagnosis and real-time disease monitoring, which offer several advantages such as minimally invasive genomic profiling, earlier intervention, continuous monitoring of treatment response and rapid identification of therapy resistance across various cancer types.
  • For instance, Guardant Health further expanded clinical use of its Guardant360 liquid biopsy platform to enable more comprehensive genomic profiling of various solid tumors to assist in precision treatment selection and ongoing disease monitoring.
  • The rising use of liquid biopsy is helping to improve early diagnosis, providing treatment monitoring and speeding up the delivery of personalized cancer care.                           

Regional Analysis of Global Personalized Oncology Market

  • North America holds the largest share of the global personalized oncology market owing to its well-established precision medicine infrastructure, extensive use of genomic profiling and companion diagnostics, presence of major biotechnology and pharmaceutical companies, and advanced clinical research capabilities. The market leadership in the region is strengthened by high use of biomarker-driven therapies, good reimbursement policies and a strong collaboration across the healthcare sector and research institutions. North America's healthcare market dominance is further bolstered by advanced healthcare infrastructure and ongoing precision medicine advancements.
  • The Asia Pacific region is the fastest growing region, driven by a growing number of cancer cases, high investment in genomic medicine, increasing access to next-generation sequencing technologies, better healthcare infrastructure, and growing government support for precision medicine efforts. The rapid adoption of personalized diagnostics and targeted therapies is accelerating market expansion across the region.       

Prominent players operating in the global personalized oncology market is AstraZeneca PLC, Bristol-Myers Squibb Company, CTOAM, Foundation Medicine, Inc., Illumina, Inc., Novartis AG, Thermo Fisher Scientific Inc., Other Key Players.      

The global personalized oncology market has been segmented as follows:

Global Personalized Oncology Market Analysis, By Component

  • Diagnostics
    • Companion Diagnostics
    • Molecular Diagnostic Tests
    • Genomic Sequencing Kits
    • Liquid Biopsy Tests
    • Biomarker Testing Solutions
    • Immunohistochemistry (IHC) Assays
    • PCR-Based Diagnostic Kits
    • Fluorescence in Situ Hybridization (FISH) Assays
    • Others
  • Therapeutics
    • Targeted Therapy Drugs
    • Immuno-Oncology Therapeutics
    • Hormonal Therapy Products
    • Precision Chemotherapy Solutions
    • Cell & Gene Therapy Products
    • Personalized Cancer Vaccines
    • Combination Therapy Products
    • Others
  • Software & Digital Platforms
    • Bioinformatics Software
    • Clinical Decision Support Software
    • Genomic Data Analysis Platforms
    • AI-Based Oncology Analytics Software
    • Molecular Tumor Board Platforms
    • Patient Data Management Software
    • Precision Medicine Workflow Software
    • Others
  • Services
    • Genomic Testing Services
    • Biomarker Analysis Services
    • Bioinformatics & Data Interpretation Services
    • Clinical Consulting Services
    • Companion Diagnostic Development Services
    • Laboratory Testing Services
    • Technical Support & Training Services
    • Regulatory & Compliance Services
    • Others

Global Personalized Oncology Market Analysis, By Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Fluorescence in Situ Hybridization (FISH)
  • Companion Diagnostics
  • Liquid Biopsy
  • AI & Machine Learning
  • Multi-Omics Analysis
  • Bioinformatics
  • Others

Global Personalized Oncology Market Analysis, By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Blood Cancer (Leukemia, Lymphoma & Myeloma)
  • Ovarian Cancer
  • Melanoma
  • Pancreatic Cancer
  • Liver Cancer
  • Gastric Cancer
  • Other Cancers

Global Personalized Oncology Market Analysis, By Therapy Type

  • Targeted Therapy
  • Immunotherapy
  • Hormone Therapy
  • Chemotherapy
  • Cell & Gene Therapy
  • Combination Therapy
  • Others

Global Personalized Oncology Market Analysis, By Biomarker Type

  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Transcriptomic Biomarkers
  • Epigenetic Biomarkers
  • Metabolomic Biomarkers
  • Others

Global Personalized Oncology Market Analysis, By Application

  • Cancer Diagnosis
  • Treatment Selection
  • Companion Diagnostics
  • Prognostic Assessment
  • Therapy Response Monitoring
  • Disease Recurrence Monitoring
  • Drug Discovery & Development
  • Clinical Research
  • Others

Global Personalized Oncology Market Analysis, By End User

  • Hospitals
  • Cancer Specialty Centers
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Others

Global Personalized Oncology Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Personalized Oncology Market Outlook
      • 2.1.1. Personalized Oncology Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Increasing adoption of comprehensive genomic profiling and next-generation sequencing (NGS)
        • 4.1.1.2. Growing use of companion diagnostics and biomarker-guided targeted therapies
        • 4.1.1.3. Expanding adoption of liquid biopsy for early cancer detection and disease monitoring
      • 4.1.2. Restraints
        • 4.1.2.1. High cost of genomic testing and personalized cancer therapies
        • 4.1.2.2. Limited standardization in multi-omic data interpretation and clinical validation
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Eco-system Analysis         
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Personalized Oncology Market Demand
      • 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Personalized Oncology Market Analysis, by Component
    • 6.1. Key Segment Analysis
    • 6.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
      • 6.2.1. Diagnostics
        • 6.2.1.1. Companion Diagnostics
        • 6.2.1.2. Molecular Diagnostic Tests
        • 6.2.1.3. Genomic Sequencing Kits
        • 6.2.1.4. Liquid Biopsy Tests
        • 6.2.1.5. Biomarker Testing Solutions
        • 6.2.1.6. Immunohistochemistry (IHC) Assays
        • 6.2.1.7. PCR-Based Diagnostic Kits
        • 6.2.1.8. Fluorescence in Situ Hybridization (FISH) Assays
        • 6.2.1.9. Others
      • 6.2.2. Therapeutics
        • 6.2.2.1. Targeted Therapy Drugs
        • 6.2.2.2. Immuno-Oncology Therapeutics
        • 6.2.2.3. Hormonal Therapy Products
        • 6.2.2.4. Precision Chemotherapy Solutions
        • 6.2.2.5. Cell & Gene Therapy Products
        • 6.2.2.6. Personalized Cancer Vaccines
        • 6.2.2.7. Combination Therapy Products
        • 6.2.2.8. Others
      • 6.2.3. Software & Digital Platforms
        • 6.2.3.1. Bioinformatics Software
        • 6.2.3.2. Clinical Decision Support Software
        • 6.2.3.3. Genomic Data Analysis Platforms
        • 6.2.3.4. AI-Based Oncology Analytics Software
        • 6.2.3.5. Molecular Tumor Board Platforms
        • 6.2.3.6. Patient Data Management Software
        • 6.2.3.7. Precision Medicine Workflow Software
        • 6.2.3.8. Others
      • 6.2.4. Services
        • 6.2.4.1. Genomic Testing Services
        • 6.2.4.2. Biomarker Analysis Services
        • 6.2.4.3. Bioinformatics & Data Interpretation Services
        • 6.2.4.4. Clinical Consulting Services
        • 6.2.4.5. Companion Diagnostic Development Services
        • 6.2.4.6. Laboratory Testing Services
        • 6.2.4.7. Technical Support & Training Services
        • 6.2.4.8. Regulatory & Compliance Services
        • 6.2.4.9. Others         
  • 7. Global Personalized Oncology Market Analysis, by Technology
    • 7.1. Key Segment Analysis
    • 7.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
      • 7.2.1. Next-Generation Sequencing (NGS)
      • 7.2.2. Polymerase Chain Reaction (PCR)
      • 7.2.3. Immunohistochemistry (IHC)
      • 7.2.4. Fluorescence in Situ Hybridization (FISH)
      • 7.2.5. Companion Diagnostics
      • 7.2.6. Liquid Biopsy
      • 7.2.7. AI & Machine Learning
      • 7.2.8. Multi-Omics Analysis
      • 7.2.9. Bioinformatics
      • 7.2.10. Others
  • 8. Global Personalized Oncology Market Analysis, by Cancer Type
    • 8.1. Key Segment Analysis
    • 8.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Cancer Type, 2021-2035
      • 8.2.1. Breast Cancer
      • 8.2.2. Lung Cancer
      • 8.2.3. Colorectal Cancer
      • 8.2.4. Prostate Cancer
      • 8.2.5. Blood Cancer (Leukemia, Lymphoma & Myeloma)
      • 8.2.6. Ovarian Cancer
      • 8.2.7. Melanoma
      • 8.2.8. Pancreatic Cancer
      • 8.2.9. Liver Cancer
      • 8.2.10. Gastric Cancer
      • 8.2.11. Other Cancers
  • 9. Global Personalized Oncology Market Analysis, by Therapy Type
    • 9.1. Key Segment Analysis
    • 9.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapy Type, 2021-2035
      • 9.2.1. Targeted Therapy
      • 9.2.2. Immunotherapy
      • 9.2.3. Hormone Therapy
      • 9.2.4. Chemotherapy
      • 9.2.5. Cell & Gene Therapy
      • 9.2.6. Combination Therapy
      • 9.2.7. Others
  • 10. Global Personalized Oncology Market Analysis, by Biomarker Type
    • 10.1. Key Segment Analysis
    • 10.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Biomarker Type, 2021-2035
      • 10.2.1. Genomic Biomarkers
      • 10.2.2. Proteomic Biomarkers
      • 10.2.3. Transcriptomic Biomarkers
      • 10.2.4. Epigenetic Biomarkers
      • 10.2.5. Metabolomic Biomarkers
      • 10.2.6. Others
  • 11. Global Personalized Oncology Market Analysis, by Application
    • 11.1. Key Segment Analysis
    • 11.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
      • 11.2.1. Cancer Diagnosis
      • 11.2.2. Treatment Selection
      • 11.2.3. Companion Diagnostics
      • 11.2.4. Prognostic Assessment
      • 11.2.5. Therapy Response Monitoring
      • 11.2.6. Disease Recurrence Monitoring
      • 11.2.7. Drug Discovery & Development
      • 11.2.8. Clinical Research
      • 11.2.9. Others
  • 12. Global Personalized Oncology Market Analysis, by End User
    • 12.1. Key Segment Analysis
    • 12.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 12.2.1. Hospitals
      • 12.2.2. Cancer Specialty Centers
      • 12.2.3. Diagnostic Laboratories
      • 12.2.4. Academic & Research Institutes
      • 12.2.5. Pharmaceutical & Biotechnology Companies
      • 12.2.6. Contract Research Organizations (CROs)
      • 12.2.7. Others
  • 13. Global Personalized Oncology Market Analysis, by Region
    • 13.1. Key Findings
    • 13.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 13.2.1. North America
      • 13.2.2. Europe
      • 13.2.3. Asia Pacific
      • 13.2.4. Middle East
      • 13.2.5. Africa
      • 13.2.6. South America
  • 14. North America Personalized Oncology Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. North America Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Component
      • 14.3.2. Technology
      • 14.3.3. Cancer Type
      • 14.3.4. Therapy Type
      • 14.3.5. Biomarker Type
      • 14.3.6. Application
      • 14.3.7. End User
      • 14.3.8. Country
        • 14.3.8.1. USA
        • 14.3.8.2. Canada
        • 14.3.8.3. Mexico
    • 14.4. USA Personalized Oncology Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Component
      • 14.4.3. Technology
      • 14.4.4. Cancer Type
      • 14.4.5. Therapy Type
      • 14.4.6. Biomarker Type
      • 14.4.7. Application
      • 14.4.8. End User
    • 14.5. Canada Personalized Oncology Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Component
      • 14.5.3. Technology
      • 14.5.4. Cancer Type
      • 14.5.5. Therapy Type
      • 14.5.6. Biomarker Type
      • 14.5.7. Application
      • 14.5.8. End User
    • 14.6. Mexico Personalized Oncology Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Component
      • 14.6.3. Technology
      • 14.6.4. Cancer Type
      • 14.6.5. Therapy Type
      • 14.6.6. Biomarker Type
      • 14.6.7. Application
      • 14.6.8. End User
  • 15. Europe Personalized Oncology Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Europe Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Component
      • 15.3.2. Technology
      • 15.3.3. Cancer Type
      • 15.3.4. Therapy Type
      • 15.3.5. Biomarker Type
      • 15.3.6. Application
      • 15.3.7. End User
      • 15.3.8. Country
        • 15.3.8.1. Germany
        • 15.3.8.2. United Kingdom
        • 15.3.8.3. France
        • 15.3.8.4. Italy
        • 15.3.8.5. Spain
        • 15.3.8.6. Netherlands
        • 15.3.8.7. Nordic Countries
        • 15.3.8.8. Poland
        • 15.3.8.9. Russia & CIS
        • 15.3.8.10. Rest of Europe
    • 15.4. Germany Personalized Oncology Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Component
      • 15.4.3. Technology
      • 15.4.4. Cancer Type
      • 15.4.5. Therapy Type
      • 15.4.6. Biomarker Type
      • 15.4.7. Application
      • 15.4.8. End User
    • 15.5. United Kingdom Personalized Oncology Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Component
      • 15.5.3. Technology
      • 15.5.4. Cancer Type
      • 15.5.5. Therapy Type
      • 15.5.6. Biomarker Type
      • 15.5.7. Application
      • 15.5.8. End User
    • 15.6. France Personalized Oncology Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Component
      • 15.6.3. Technology
      • 15.6.4. Cancer Type
      • 15.6.5. Therapy Type
      • 15.6.6. Biomarker Type
      • 15.6.7. Application
      • 15.6.8. End User
    • 15.7. Italy Personalized Oncology Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Component
      • 15.7.3. Technology
      • 15.7.4. Cancer Type
      • 15.7.5. Therapy Type
      • 15.7.6. Biomarker Type
      • 15.7.7. Application
      • 15.7.8. End User
    • 15.8. Spain Personalized Oncology Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Component
      • 15.8.3. Technology
      • 15.8.4. Cancer Type
      • 15.8.5. Therapy Type
      • 15.8.6. Biomarker Type
      • 15.8.7. Application
      • 15.8.8. End User
    • 15.9. Netherlands Personalized Oncology Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Component
      • 15.9.3. Technology
      • 15.9.4. Cancer Type
      • 15.9.5. Therapy Type
      • 15.9.6. Biomarker Type
      • 15.9.7. Application
      • 15.9.8. End User
    • 15.10. Nordic Countries Personalized Oncology Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Component
      • 15.10.3. Technology
      • 15.10.4. Cancer Type
      • 15.10.5. Therapy Type
      • 15.10.6. Biomarker Type
      • 15.10.7. Application
      • 15.10.8. End User
    • 15.11. Poland Personalized Oncology Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Component
      • 15.11.3. Technology
      • 15.11.4. Cancer Type
      • 15.11.5. Therapy Type
      • 15.11.6. Biomarker Type
      • 15.11.7. Application
      • 15.11.8. End User
    • 15.12. Russia & CIS Personalized Oncology Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Component
      • 15.12.3. Technology
      • 15.12.4. Cancer Type
      • 15.12.5. Therapy Type
      • 15.12.6. Biomarker Type
      • 15.12.7. Application
      • 15.12.8. End User
    • 15.13. Rest of Europe Personalized Oncology Market
      • 15.13.1. Component
      • 15.13.2. Component
      • 15.13.3. Technology
      • 15.13.4. Cancer Type
      • 15.13.5. Therapy Type
      • 15.13.6. Biomarker Type
      • 15.13.7. Application
      • 15.13.8. End User
  • 16. Asia Pacific Personalized Oncology Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Asia Pacific Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Component
      • 16.3.2. Technology
      • 16.3.3. Cancer Type
      • 16.3.4. Therapy Type
      • 16.3.5. Biomarker Type
      • 16.3.6. Application
      • 16.3.7. End User
      • 16.3.8. Country
        • 16.3.8.1. China
        • 16.3.8.2. India
        • 16.3.8.3. Japan
        • 16.3.8.4. South Korea
        • 16.3.8.5. Australia and New Zealand
        • 16.3.8.6. Indonesia
        • 16.3.8.7. Malaysia
        • 16.3.8.8. Thailand
        • 16.3.8.9. Vietnam
        • 16.3.8.10. Rest of Asia Pacific
    • 16.4. China Personalized Oncology Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Component
      • 16.4.3. Technology
      • 16.4.4. Cancer Type
      • 16.4.5. Therapy Type
      • 16.4.6. Biomarker Type
      • 16.4.7. Application
      • 16.4.8. End User
    • 16.5. India Personalized Oncology Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Component
      • 16.5.3. Technology
      • 16.5.4. Cancer Type
      • 16.5.5. Therapy Type
      • 16.5.6. Biomarker Type
      • 16.5.7. Application
      • 16.5.8. End User
    • 16.6. Japan Personalized Oncology Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Component
      • 16.6.3. Technology
      • 16.6.4. Cancer Type
      • 16.6.5. Therapy Type
      • 16.6.6. Biomarker Type
      • 16.6.7. Application
      • 16.6.8. End User
    • 16.7. South Korea Personalized Oncology Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Component
      • 16.7.3. Technology
      • 16.7.4. Cancer Type
      • 16.7.5. Therapy Type
      • 16.7.6. Biomarker Type
      • 16.7.7. Application
      • 16.7.8. End User
    • 16.8. Australia and New Zealand Personalized Oncology Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Component
      • 16.8.3. Technology
      • 16.8.4. Cancer Type
      • 16.8.5. Therapy Type
      • 16.8.6. Biomarker Type
      • 16.8.7. Application
      • 16.8.8. End User
    • 16.9. Indonesia Personalized Oncology Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Component
      • 16.9.3. Technology
      • 16.9.4. Cancer Type
      • 16.9.5. Therapy Type
      • 16.9.6. Biomarker Type
      • 16.9.7. Application
      • 16.9.8. End User
    • 16.10. Malaysia Personalized Oncology Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Component
      • 16.10.3. Technology
      • 16.10.4. Cancer Type
      • 16.10.5. Therapy Type
      • 16.10.6. Biomarker Type
      • 16.10.7. Application
      • 16.10.8. End User
    • 16.11. Thailand Personalized Oncology Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Component
      • 16.11.3. Technology
      • 16.11.4. Cancer Type
      • 16.11.5. Therapy Type
      • 16.11.6. Biomarker Type
      • 16.11.7. Application
      • 16.11.8. End User
    • 16.12. Vietnam Personalized Oncology Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Component
      • 16.12.3. Technology
      • 16.12.4. Cancer Type
      • 16.12.5. Therapy Type
      • 16.12.6. Biomarker Type
      • 16.12.7. Application
      • 16.12.8. End User
    • 16.13. Rest of Asia Pacific Personalized Oncology Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Component
      • 16.13.3. Technology
      • 16.13.4. Cancer Type
      • 16.13.5. Therapy Type
      • 16.13.6. Biomarker Type
      • 16.13.7. Application
      • 16.13.8. End User
  • 17. Middle East Personalized Oncology Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Middle East Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Component
      • 17.3.2. Technology
      • 17.3.3. Cancer Type
      • 17.3.4. Therapy Type
      • 17.3.5. Biomarker Type
      • 17.3.6. Application
      • 17.3.7. End User
      • 17.3.8. Country
        • 17.3.8.1. Turkey
        • 17.3.8.2. UAE
        • 17.3.8.3. Saudi Arabia
        • 17.3.8.4. Israel
        • 17.3.8.5. Rest of Middle East
    • 17.4. Turkey Personalized Oncology Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Component
      • 17.4.3. Technology
      • 17.4.4. Cancer Type
      • 17.4.5. Therapy Type
      • 17.4.6. Biomarker Type
      • 17.4.7. Application
      • 17.4.8. End User
    • 17.5. UAE Personalized Oncology Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Component
      • 17.5.3. Technology
      • 17.5.4. Cancer Type
      • 17.5.5. Therapy Type
      • 17.5.6. Biomarker Type
      • 17.5.7. Application
      • 17.5.8. End User
    • 17.6. Saudi Arabia Personalized Oncology Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Component
      • 17.6.3. Technology
      • 17.6.4. Cancer Type
      • 17.6.5. Therapy Type
      • 17.6.6. Biomarker Type
      • 17.6.7. Application
      • 17.6.8. End User
    • 17.7. Israel Personalized Oncology Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Component
      • 17.7.3. Technology
      • 17.7.4. Cancer Type
      • 17.7.5. Therapy Type
      • 17.7.6. Biomarker Type
      • 17.7.7. Application
      • 17.7.8. End User
    • 17.8. Rest of Middle East Personalized Oncology Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Component
      • 17.8.3. Technology
      • 17.8.4. Cancer Type
      • 17.8.5. Therapy Type
      • 17.8.6. Biomarker Type
      • 17.8.7. Application
      • 17.8.8. End User
  • 18. Africa Personalized Oncology Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Africa Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Component
      • 18.3.2. Technology
      • 18.3.3. Cancer Type
      • 18.3.4. Therapy Type
      • 18.3.5. Biomarker Type
      • 18.3.6. Application
      • 18.3.7. End User
      • 18.3.8. Country
        • 18.3.8.1. South Africa
        • 18.3.8.2. Egypt
        • 18.3.8.3. Nigeria
        • 18.3.8.4. Algeria
        • 18.3.8.5. Rest of Africa
    • 18.4. South Africa Personalized Oncology Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Component
      • 18.4.3. Technology
      • 18.4.4. Cancer Type
      • 18.4.5. Therapy Type
      • 18.4.6. Biomarker Type
      • 18.4.7. Application
      • 18.4.8. End User
    • 18.5. Egypt Personalized Oncology Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Component
      • 18.5.3. Technology
      • 18.5.4. Cancer Type
      • 18.5.5. Therapy Type
      • 18.5.6. Biomarker Type
      • 18.5.7. Application
      • 18.5.8. End User
    • 18.6. Nigeria Personalized Oncology Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Component
      • 18.6.3. Technology
      • 18.6.4. Cancer Type
      • 18.6.5. Therapy Type
      • 18.6.6. Biomarker Type
      • 18.6.7. Application
      • 18.6.8. End User
    • 18.7. Algeria Personalized Oncology Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Component
      • 18.7.3. Technology
      • 18.7.4. Cancer Type
      • 18.7.5. Therapy Type
      • 18.7.6. Biomarker Type
      • 18.7.7. Application
      • 18.7.8. End User
    • 18.8. Rest of Africa Personalized Oncology Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Component
      • 18.8.3. Technology
      • 18.8.4. Cancer Type
      • 18.8.5. Therapy Type
      • 18.8.6. Biomarker Type
      • 18.8.7. Application
      • 18.8.8. End User
  • 19. South America Personalized Oncology Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. South America Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Component
      • 19.3.2. Technology
      • 19.3.3. Cancer Type
      • 19.3.4. Therapy Type
      • 19.3.5. Biomarker Type
      • 19.3.6. Application
      • 19.3.7. End User
      • 19.3.8. Country
        • 19.3.8.1. Brazil
        • 19.3.8.2. Argentina
        • 19.3.8.3. Rest of South America
    • 19.4. Brazil Personalized Oncology Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Component
      • 19.4.3. Technology
      • 19.4.4. Cancer Type
      • 19.4.5. Therapy Type
      • 19.4.6. Biomarker Type
      • 19.4.7. Application
      • 19.4.8. End User
    • 19.5. Argentina Personalized Oncology Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Component
      • 19.5.3. Technology
      • 19.5.4. Cancer Type
      • 19.5.5. Therapy Type
      • 19.5.6. Biomarker Type
      • 19.5.7. Application
      • 19.5.8. End User
    • 19.6. Rest of South America Personalized Oncology Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Component
      • 19.6.3. Technology
      • 19.6.4. Cancer Type
      • 19.6.5. Therapy Type
      • 19.6.6. Biomarker Type
      • 19.6.7. Application
      • 19.6.8. End User
  • 20. Key Players/ Company Profile
    • 20.1. AstraZeneca PLC
      • 20.1.1. Company Details/ Overview
      • 20.1.2. Company Financials
      • 20.1.3. Key Customers and Competitors
      • 20.1.4. Business/ Industry Portfolio
      • 20.1.5. Product Portfolio/ Specification Details
      • 20.1.6. Pricing Data
      • 20.1.7. Strategic Overview
      • 20.1.8. Recent Developments
    • 20.2. Bristol-Myers Squibb Company
    • 20.3. CTOAM
    • 20.4. Foundation Medicine, Inc.
    • 20.5. Illumina, Inc.
    • 20.6. Novartis AG
    • 20.7. Thermo Fisher Scientific Inc.
    • 20.8. Other Key Players

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation